Tempus AI Stock Pops As FDA Win Fuels Growth Story

Tempus AI Inc. surged as pivotal AI healthcare partnership news boosted investor optimism, with stocks have been trading up by 9.81 percent

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading TEM

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways Traders Should Watch

Shares ripped over 6% after FDA approval for a tumor-only use of Tempus AI’s xT CDx sequencing test for solid tumors, a major validation for its oncology platform.
An upsized $400M 0% convertible notes deal due 2032 lifted premarket trading, signaling strong demand for TEM’s growth story despite future dilution risk.
A deeper Bristol Myers Squibb collaboration puts Tempus AI’s multimodal data at the center of five oncology and neuroscience programs, aiming to boost trial success rates.
A new Alzheimer’s-focused Tempus Next care-gap program, built around Quanterix’s LucentAD blood test, pushes the Tempus AI platform further into neurology workflows.
With $1.2B in 2025 revenue and 2026 guidance near $1.59B plus positive adjusted EBITDA, Tempus AI is trading like a scaled AI data platform, not a tiny biotech flyer.

Live Update At 12:32:58 EDT: On Thursday, June 04, 2026 Tempus AI Inc. stock [NASDAQ: TEM] is trending up by 9.81%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Tempus AI, trading under ticker TEM, has been acting like a momentum name with real numbers behind it. On 2026/06/03, TEM closed at $47.51. One day later it finished at $52.17, a sharp move that confirms traders are treating every catalyst as a breakout opportunity, not a fade.

Looking across the recent daily chart, TEM has pushed from the low $40s in mid‑May into the low $50s, with several high‑range closes. That tells you dip buyers have been in control and shorts have been on defense. Intraday on the latest session, Tempus AI opened just under $47 and steadily grinded higher, with only shallow pullbacks. For active traders, that pattern — higher lows all morning, then tight consolidation above $52 — is classic trend‑day behavior.

More Breaking News

Under the hood, Tempus AI reported about $1.27B in trailing revenue, with a price‑to‑sales ratio around 6.5. The company is still losing money, with negative margins and roughly -$125.9M net income last quarter, but it is posting triple‑digit gross margins and has a healthy current ratio of 3.3. For traders, that mix says “high‑growth platform still burning cash, but not desperate,” which is exactly the kind of profile that can support big swings when news hits.

Why Traders Are Watching Tempus AI Now

Tempus AI has stacked several high‑impact catalysts in a short window, and the tape is reacting. The biggest spark came when Tempus AI secured FDA approval for a tumor‑only indication on its xT CDx next‑generation sequencing platform for solid tumors. The stock jumped more than 6% on that headline. In this market, an FDA green light is not just a regulatory box checked — it’s proof the core tech works and can be sold into oncology clinics at scale. Traders see that as de‑risking and often re‑rate the whole story higher.

Around the same time, Tempus AI priced an upsized $400M 0% convertible senior notes deal due 2032, with TEM trading up over 1% in the premarket. A zero‑coupon structure tells you two things. First, the company has enough credibility to raise large, cheap capital. Second, equity holders have to factor in eventual dilution down the road. Short‑term though, the market framed it as firepower for more growth, not a distress move.

Tempus AI is also tightening its grip on pharma workflows. The expanded collaboration with Bristol Myers Squibb pulls Tempus AI’s platform into five oncology and neuroscience programs, using multimodal real‑world data to shape clinical trial design and bump the odds of technical and regulatory success. That is exactly the kind of sticky, recurring relationship traders like to see from a data platform name.

On the neurology side, Tempus AI is rolling out a Tempus Next care‑gap program for Alzheimer’s disease and integrating Quanterix’s LucentAD Complete blood biomarker into its ordering platform. That matters because it shows TEM is not just an oncology lab — it’s trying to be a cross‑specialty AI rails provider, from oncology to cardiology to neuropsychiatry. Add in the profile as one of the most‑watched AI medical platforms, with $1.2B in 2025 revenue and guidance near $1.59B for 2026 plus positive adjusted EBITDA, and you can see why traders are crowding into Tempus AI on every breakout.

Conclusion

For active traders, Tempus AI is a textbook high‑growth, catalyst‑driven AI‑healthcare stock. The FDA win on xT CDx gave the market a clean signal that this is a real commercial platform, not just a slide deck. The $400M convertible notes deal showed that capital markets desks are willing to write big zero‑coupon checks to TEM, which usually keeps the growth engine running longer than the average small‑cap biotech. Layer on the Bristol Myers Squibb expansion and the Alzheimer’s care‑gap program with Quanterix’s LucentAD test, and Tempus AI now has multiple, credible storylines across oncology and neurology for traders to track.

Financially, Tempus AI is still losing money, but revenue scale near the $1.2B mark and guidance around $1.59B for 2026, plus positive adjusted EBITDA, push it into a different bucket than early‑stage clinical names. It trades like a data‑rich AI platform with optionality, and that usually means bigger ranges and sharper reactions on news.

For anyone studying this ticker, the playbook is clear: respect the volatility, map your levels, and react — don’t predict. As Tim Sykes likes to hammer home, “Patterns repeat, but only if you’re prepared. Study the past, stay disciplined, and never risk what you can’t afford to lose.” As Tim Bohen, lead trainer with StocksToTrade says, “If you’re still guessing at the end of your analysis, it’s probably not a trade worth taking.” That combination of pattern recognition and strict trade selection keeps you from forcing A+ setups where they don’t exist. That mindset fits Tempus AI perfectly right now.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!